journal article·2025-12-23

A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection

Alfred Akinlalu, Komila Rasuleva, Emmanuel Ogberefor, Tommy Gao, Haiyong Han, Pankaj K Singh, Christopher H. Lieu, Christina Coughlan, Todd M. Pitts, Dali Sun

ACS Nano· Volume 19· Issue 50
Publisher page

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to detect, with significant limitations compared to screening methods for lung, breast, colon, and cervical cancers. Current methods are often plagued by high false-positive rates, necessitating costly, complex, and invasive confirmatory procedures. These challenges arise from the low incidence of PDAC and the need for highly specific and sensitive screening methods. To address these limitations, we developed EV-FRET, a fluorescence resonance energy transfer (FRET)-based assay designed as a rapid, specific, noninvasive, single-step, and low-cost detection method for PDAC. EV-FRET targets extracellular vesicles (EVs), small vesicles secreted by cells, including tumor cells, leveraging their unique size (∼160 nm) and composition for cancer detection. The EV-FRET assay targets two key markers: β-sheet-rich tumorous proteins (pan-cancer) and N -acetyl- d -galactosamine on epithelial cells (pancreas-specific), using thioflavin T and Dolichos biflorus agglutinin conjugated with fluorescein isothiocyanate fluorophores, which generate a FRET signal exclusively in PDAC-derived EVs within the circulating system. EV-FRET demonstrated superior diagnostic accuracy, achieving an area under the curve of 0.95 compared to 0.72 for CA19–9, the current clinical standard for PDAC detection. The assay offers additional advantages, including high reproducibility (coefficient of variation <4%), fast processing time (<15 min), low cost (estimated reagent cost < $15/test), and a simple, single-step operation that eliminates the need for EV enrichment or isolation. By integrating organ-specific markers and a tumor-specific biomarker, EV-FRET provides a scalable and highly specific diagnostic solution for pancreatic cancer. These features position EV-FRET as a transformative tool in cancer diagnostics, with the potential to significantly improve patient outcomes through more precise detection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biomedical Focus, Department of Electrical and Computer Engineering, University of Denver, 2155 E Wesley Ave., Denver, Colorado 80208, United States

Knoebel Institute of Healthy Aging, University of Denver, 2155 E Wesley Ave., Denver, Colorado 80208, United States

Biomedical Engineering Program, North Dakota State University, 1401 Centennial Blvd, Engineering Administration, Room 23, Fargo, North Dakota 58102, United States

Translational Genomics Research Institute (TGen), 445 North fifth Street, Phoenix, Arizona 85004, United States

University of Oklahoma Health Sciences Center, 1100 N Lindsay Ave, Oklahoma City, Oklahoma 73104, United States

Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, Colorado 80045, United States

Funding

Division of Cancer Prevention, National Cancer Institute · Division of Chemical, Bioengineering, Environmental, and Transport Systems · National Institute of General Medical Sciences · Advanced Industries Grant Award from Colorado Office of Economic Development and International Trade

References (41)

Show source-provided references
1. 10.4251/wjgo.v12.i2.17310.4251/wjgo.v12.i2.173 ↗
2. 10.1186/s13014-019-1345-610.1186/s13014-019-1345-6 ↗
3. American Cancer Society Facts About Pancreatic Cancer . https://www.cancer.net/cancer-types/pancreatic-cancer/statistics
4. 10.1016/S0140-6736(16)00141-010.1016/S0140-6736(16)00141-0 ↗
5. 10.1016/j.ctrv.2021.10219310.1016/j.ctrv.2021.102193 ↗
6. 10.1038/s43856-023-00237-510.1038/s43856-023-00237-5 ↗
7. 10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer ↗
8. 10.3390/cancers1509244610.3390/cancers15092446 ↗
9. 10.1158/1055-9965.EPI-20-007410.1158/1055-9965.EPI-20-0074 ↗
10. 10.1158/2767-9764.CRC-22-019010.1158/2767-9764.CRC-22-0190 ↗
11. 10.3390/cancers1311272210.3390/cancers13112722 ↗
12. 10.3390/ijms2205265510.3390/ijms22052655 ↗
13. 10.7150/ijbs.2779610.7150/ijbs.27796 ↗
14. 10.1021/pr300330z10.1021/pr300330z ↗
15. 10.1021/pr900715p10.1021/pr900715p ↗
16. 10.1021/acssensors.1c0202210.1021/acssensors.1c02022 ↗
17. 10.3390/ijms1604671810.3390/ijms16046718 ↗
18. 10.1021/ja994397m10.1021/ja994397m ↗
19. 10.1016/j.cclet.2021.12.06110.1016/j.cclet.2021.12.061 ↗
20. 10.1083/jcb.20021014010.1083/jcb.200210140 ↗
21. 10.1002/978352765602810.1002/9783527656028 ↗
22. 10.1007/s12551-017-0252-z10.1007/s12551-017-0252-z ↗
23. 10.1021/acschemneuro.0c0022610.1021/acschemneuro.0c00226 ↗
24. Fang C. · Am. J. Transl Res. · 2023 · 15 · 694
25. 10.1080/20013078.2017.134408710.1080/20013078.2017.1344087 ↗
26. 10.1016/j.trac.2019.11577710.1016/j.trac.2019.115777 ↗
27. 10.1038/s41592-019-0530-810.1038/s41592-019-0530-8 ↗
28. 10.1038/onc.2011.19410.1038/onc.2011.194 ↗
29. 10.1084/jem.2021150510.1084/jem.20211505 ↗
30. 10.4081/ejh.2024.395910.4081/ejh.2024.3959 ↗
31. 10.1074/jbc.M20067320010.1074/jbc.M200673200 ↗
32. 10.2174/18715200878333086010.2174/187152008783330860 ↗
33. 10.1158/0008-5472.CAN-21-194010.1158/0008-5472.CAN-21-1940 ↗
34. ImajeJ Coloc 2 https://imagej.net/plugins/coloc-2
35. 10.1007/978-1-4939-7652-2_810.1007/978-1-4939-7652-2_8 ↗
36. 10.1186/s40364-022-00404-110.1186/s40364-022-00404-1 ↗
37. 10.1002/9780470683019.ch910.1002/9780470683019.ch9 ↗
38. 10.1021/acssensors.1c0202210.1021/acssensors.1c02022 ↗
39. 10.1021/acs.analchem.9b0485210.1021/acs.analchem.9b04852 ↗
40. 10.1002/cyto.a.2074710.1002/cyto.a.20747 ↗
41. Abràmoff M. D. · Biophotonics Int. · 2004 · 11 · 36